Vivani Medical, Inc. (VANI)
| Previous close | 1.2500 |
| Open | 1.2300 |
| Bid | 1.1600 x 400 |
| Ask | 1.3000 x 400 |
| Day's range | 1.2300 - 1.2325 |
| 52-week range | 0.8400 - 7.8000 |
| Volume | |
| Avg. volume | 397,920 |
| Market cap | 67.761M |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.5000 |
| Earnings date | 12 Aug 2024 - 16 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 8.00 |
Business WireVivani Medical Announces FDA Clears Investigational New Drug Application and Lifts Clinical Hold for NPM-119, a Miniature Long-Term Subdermal GLP-1 Drug Implant
ALAMEDA, Calif., June 13, 2024--Vivani Medical, Inc. (Nasdaq: VANI) ("Vivani" or the "Company"), an innovative, biopharmaceutical company developing novel, long-term drug implants, today announced the U.S. Food and Drug Administration has cleared the Investigational New Drug Application ("IND") and lifted the clinical hold on NPM-119 to allow initiation of LIBERATE-1™, a Phase 1 clinical trial to assess the safety, tolerability and pharmacokinetics of NPM-119 (exenatide), the Company’s miniature
Simply Wall St.Insider Stock Buying Reaches US$751.8k On Vivani Medical
It is usually uneventful when a single insider buys stock. However, When quite a few insiders buy shares, as it...
Business WireVivani Medical Announces Publication of Positive Weight Loss Data Supporting Potential Veterinary Use of OKV-119 Miniature, Long-term GLP-1 Implant
ALAMEDA, Calif., May 28, 2024--Vivani Medical, Inc. (Nasdaq: VANI) ("Vivani" or the "Company"), a biopharmaceutical company developing miniaturized, long-term drug implants including its lead asset NPM-115 for chronic weight management in obese or overweight human patients with one or more risk factors, today announced the publication of positive proof-of-concept weight loss data with OKV-119, a miniature, subdermal, exenatide drug implant designed to treat feline obesity and diabetes, in the pe
